Tandem study shows great improvement for high A1c

SAN DIEGO – Tandem Diabetes Care, has published the result of a meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. The results, published in Diabetes Technology & Therapeutics demonstrate the positive clinical impact of the system’s automatic correction bolusing on glucose control across a wide range of ages and demographics of people with Type 1 diabetes. People with the highest baseline blood sugar levels experienced the greatest benefit from the auto-bolus feature of the Control-IQ algorithm. “Control-IQ technology delivered the most robust improvements in those entering the study with the highest hemoglobin A1c and lowest time in range,” said Roy W. Beck, MD, PhD, executive director of the Jaeb Center for Health Research. “The high number of automatic boluses given by the system in this group likely reflect previously missed meal boluses or lack of manual correction boluses when on conventional therapy and demonstrates the substantial impact Control-IQ technology’s auto-bolusing feature can have for people struggling on a standard pump or multiple daily injections.” The analysis also showed an average increase in time in range of 2.8 hours and a reduction in A1c compared to control groups in people ages 2 to 72 years old. Improvements in time in range for subjects using Control-IQ technology (n=256) were immediate, sustained and observed across the spectrum of patient characteristics including age, race-ethnicity, parental education, family income, baseline glycated hemoglobin level, virtual vs. in-person training format, and pre-study insulin delivery method. The majority of the control group (n=113) used an insulin pump (91%), some with predictive low glucose suspend technology.